How many times should I follow up with a Sales VP (after a demo)?

Send it after the third unanswered touch, not after the first silence. Same day with the recap. A value bump 3 days later if they went quiet. After that, send a breakup note and archive it. A sales VP who wants it will answer a clean close more often than a fifth bump.

Is a breakup email the same as an unsubscribe?

No. A breakup email closes one thread. If they asked not to be contacted, honor that and remove them. Don't dress a suppression request as a cute last-chance campaign. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

Should I include a recording in the demo follow-up?

If you recorded it and they agreed, yes, plus timestamps for the two parts they cared about. A raw 40-minute link with no map is homework. Add the three bullets they'd need to brief a colleague. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

Is it okay to send this breakup email on LinkedIn instead of email?

Yes if this sales VP is actually active there and the thread isn't about long attachments. Keep the LinkedIn version even shorter. Don't paste the full email. One context line and one question is plenty. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

What should I never say in a Pharmaceuticals breakup email?

Don't use consumer-startup slang. It's a credibility leak. Telling them how to sell. They've heard it. Don't send a 19-page deck that relitigates features they skipped. Those three mistakes show up constantly in Pharmaceuticals inboxes and they all read as "this was templated."

Pharmaceuticals · Sales VP · After Demo

Breakup Email for Pharmaceuticals Sales VP: After Demo

A breakup email is a polite close-the-loop note that ends a stalled thread and leaves the door open without more chasing. For Pharmaceuticals teams, the version that works for after a demo has to respect Don't invent clinical claims. Write to the sales VP like they already have a full calendar and a reason to be cautious.

Last updated: 2026-09-02 · Reviewed by: Sales Email Template editors

We write templates the way we wrote emails on quota: short, specific, and easy to forward. When we cite research below, it is because the number changes how a buyer reads your note, not to pad the page.

Sources: HubSpot sales email benchmarks; Gong follow-up research

Why does this breakup email work for a Pharmaceuticals Sales VP?

Skip the fake 'I hate to bother you' prologue.
Speaks to follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick instead of a generic "value prop."
Fits how a sales VP actually reads: 70 to 90 words. Lead with the outcome.
Replay the two moments they leaned in, and the one concern they named.
Leave one useful artifact, not another pitch.

When should I send this to a Pharmaceuticals Sales VP?

Send it after the third unanswered touch, not after the first silence. Same day with the recap. A value bump 3 days later if they went quiet. For this combo, treat "Same day, then 3 days if silent" as the default, then adjust around launch calendars and review boards set speed. you don't. If you're emailing a sales VP, 70 to 90 words. Lead with the outcome. Tuesday through Thursday mid-morning local time is a safe default.

What this Sales VP actually cares about

A sales VP in Pharmaceuticals is protecting quota, forecast credibility, and rep time. They think in pipeline, ramp, and forecast risk. If you can't map your email to a number they already report, it feels like a hobby. The hook that earns a look is a stage in the funnel that's leaking, a slow follow-up SLA, or a ramp problem. The ask should stay at this size: a 15-minute look at one metric, not a platform tour. Delete trigger: Telling them how to sell. They've heard it. They think in pipeline, ramp, and forecast risk. If you can't map your email to a number they already report, it feels like a hobby.

How Pharmaceuticals changes the note

Pharmaceuticals buyers are commercial, medical, and ops leads who work under review boards and long timelines. Don't invent clinical claims. Don't treat HCPs like a funnel. If you don't know the rules, your email is a liability. A credible proof point in this vertical sounds like: cut review cycles on a leave-behind by catching claims issues before legal saw the tenth draft. Watch the language. Words that land here include MLR, label, access, HCP, congress, promotional review. If you cannot name a label update, a launch window, or a congress, wait until you can. If you cannot name a label update, a launch window, or a congress, wait until you can.

How should I customize this template before I send it?

Replace the pain line with an agency waiting on MLR while the sales team keeps asking 'is it approved yet'.
Keep the tone crisp and commercial.
Don't CC their boss as a breakup tactic.
Time it for Same day, then 3 days if silent. Same day with the recap. A value bump 3 days later if they went quiet.
Don't use consumer-startup slang. It's a credibility leak.

What mistakes should I avoid with this after demo note?

Sarcastic breakup emails feel clever to you and cheap to them.
Don't send a 19-page deck that relitigates features they skipped.
Don't use consumer-startup slang. It's a credibility leak.
Telling them how to sell. They've heard it.

How does this after demo scenario compare?

Dimension	For this template
Best send window	Same day, then 3 days if silent
Ideal length	70 to 90 words. Lead with the outcome.
Primary ask	a 15-minute look at one metric, not a platform tour
Industry metric to cite	time through MLR, access, and compliant engagement rates
Tone	Crisp and commercial. They can handle a direct ask.
Unlike after meeting	They have product context now. Speak to what they saw, not to a generic intro.
Unlike after proposal	Pricing may not be on paper yet. Don't jump to 'ready to sign.'

What should I copy and send?

Copy-ready template

Subject

Pharmaceuticals note on follow-up that ignores MLR, off-label risk,

Body

Hi [First Name],

I'll close this out on my side unless you want it left open.

I'm writing because a label update, a launch window, or a congress. In case it's useful later, here's the one-pager on cut review cycles on a leave-behind by catching claims issues before legal saw the tenth draft. No need to respond.

Given this is after a demo, ask who else needs to see it, or whether a narrower use case is the better start.

Wishing you a clean quarter either way.

Best,
[Your Name]
[Your Title]
[Your Company]

Questions people ask before they hit send

Name the situation and the business object, not your excitement. Something like "Pharmaceuticals note on follow-up that ignores MLR, off-label risk," outperforms "Just checking in" because a sales VP can decide from the preview text whether it's worth opening. Keep it under 50 characters when you can.

Related templates

Want a custom draft instead? Try the email generator.